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Organophosphate (OP) pesticide exposure
remains widespread in the United States (Barr
et al. 2004; Bradman et al. 2005; Hill et al.
1995; Loewenherz et al. 1997; Simcox et al.
1999). Pregnant women, fetuses, and children
in both urban (Berkowitz et al. 2003; Whyatt
et al. 2003) and rural agricultural populations
(Eskenazi et al. 2004; Fenske et al. 2002) are
directly exposed to pesticides, and in some
cases these exposures may exceed health-based
reference doses (Bradman et al. 2005;
Castorina et al. 2003). OP pesticide metabo-
lites have also been detected in meconium
(Whyatt and Barr 2001) and amniotic fluid
(Bradman et al. 2003). OP exposure at high
doses has profound effects, primarily on the
central nervous system (Eskenazi et al. 1999),
and there is growing information in animals
and humans suggesting that low-level chronic
exposure may affect neurodevelopment
(Eskenazi et al. 1999; Young et al. 2005).
The unique physiologic and behavioral
characteristics of children may increase their
exposures to environmental contaminants
compared with adults (National Research
Council 1993). Young children eat, drink, and
breathe more per unit of body weight than do
adults, and they also explore their environment
orally, engaging in extensive hand-to-mouth
behavior ( National Research Council 1993).
In addition, young children may be more sus-
ceptible to the adverse effects of OP exposure
than are adults, because of their lower ability
to metabolize and detoxify OP pesticides
(Padilla et al. 2000; Sheets 2000).
The human paraoxonase 1 (PON1) enzyme
(43 kDa, composed of 354 amino acids) is a
polymorphic, high-density lipoprotein-
associated esterase that metabolizes many
different substrates, including OP com-
pounds (Davies et al. 1996; Geldmacher-von
Mallinckrodt and Diepgen 1988), drugs, and
oxidized lipids (Draganov et al. 2005; Watson
et al. 1995). Studies of the PON1 enzyme,
which detoxiﬁes activated oxon forms of sev-
eral OP pesticides, including diazinon, chlor-
pyrifos, and parathion, indicate that PON1
levels in newborns are on average 3- to 4-fold
lower than those of adults (Augustinsson and
Barr 1963; Chen et al. 2003; Cole et al. 2003;
Ecobichon and Stephens 1973; Mueller et al.
1983). Newborns reach a plateau near adult
PON1 levels between 6 and 24 months of
age, suggesting that newborn children and
infants will be more susceptible to OP
compounds (Cole et al. 2003).
The PON1 gene has been mapped to chro-
mosome 7q21.3-22.1 (Humbert et al. 1993;
Primo-Parmo et al. 1996) and contains nine
exons. Recent studies suggest that some indi-
viduals may have specific PON1 genotypes
that are associated with low levels of plasma
PON1 (Brophy et al. 2001b; Deakin et al.
2003; Suehiro et al. 2000). The hydrolytic cat-
alytic efficiency of some PON1 substrates is
dependent on the single nucleotide poly-
morphism (SNP) Q192R (Li et al. 2000).
However, adults with the same PON1192
genotype can have at least a 13-fold difference
in PON1 activities (Davies et al. 1996;
Furlong et al. 2002). The C-108T polymor-
phism, in a Sp1 binding site of the promoter
region, has a major effect on the expression of
the PON1 gene. The C-108 allele expresses on
average twice as much PON1 as does the
T-108 allele (Brophy et al. 2001b; James et al.
2000). Other polymorphisms in the promoter
region (A-162G, and C-909G) may have less
significant effects on PON1 expression and
are in strong disequilibrium with C-108T
(Costa et al. 2002; James et al. 2000). The
PON1M55 allele has been associated with low
PON1 enzyme levels; however, most of this
effect is related to its strong disequilibrium
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Recent studies have demonstrated widespread pesticide exposures in pregnant women and in
children. Plasma paraoxonase 1 (PON1) plays an important role in detoxification of various
organophosphates. The goals of this study were to examine in the Center for Health Assessment
of Mothers and Children of Salinas (CHAMACOS) birth cohort of Latina mothers and their new-
borns living in the Salinas Valley, California, the frequencies of ﬁve PON1 polymorphisms in the
coding region (192QR and 55LM) and the promoter region (–162AG, –909CG , and –108CT) and to
determine their associations with PON1 plasma levels [phenylacetate arylesterase (AREase)] and
enzyme activities of paraoxonase (POase) and chlorpyrifos oxonase (CPOase). Additionally, we
report results of PON1 linkage analysis and estimate the predictive value of haplotypes for PON1
plasma levels. We found that PON1–909, PON1–108, and PON1192 had an equal frequency (0.5) of
both alleles, whereas PON1–162 and PON155 had lower variant allele frequencies (0.2). Nearly
complete linkage disequilibrium was observed among coding and promoter polymorphisms (p <
0.001), except PON1192 and PON1–162 (p > 0.4). Children’s PON1 plasma levels (AREase ranged
from 4.3 to 110.7 U/mL) were 4-fold lower than their mothers’ (19.8 to 281.4 U/mL). POase and
CPOase activities were approximately 3-fold lower in newborns than in mothers. The genetic con-
tribution to PON1 enzyme variability was higher in newborns (R2 = 25.1% by genotype and
26.3% by haplotype) than in mothers (R2 = 8.1 and 8.8%, respectively). However, haplotypes and
genotypes were comparable in predicting PON1 plasma levels in mothers and newborns. Most of
the newborn children and some pregnant women in this Latino cohort may have elevated suscepti-
bility to organophosphate toxicity because of their PON1192 genotype and low PON1 plasma
levels. Key words: chlorpyrifos, cord blood, haplotypes, Latino cohort, linkage disequilibrium,
organophosphate, paraoxonase 1 (PON1) genotype, paraoxonase activity, pesticides, PON1 poly-
morphisms, pregnancy. Environ Health Perspect 114:985–991 (2006). doi:10.1289/ehp.8540
available via http://dx.doi.org/ [Online 2 February 2006]with the T-108 allele. Recently, additional
promoter polymorphisms have been identiﬁed
(SeattleSNPs 2005); however, their inﬂuence
on PON1 levels has yet to be determined
(Jarvik GP, personal communication). Limited
information on PON1 haplotypes (Chen et al.
2005; Koda et al. 2004; Wetmur et al. 2005)
suggests that haplotypes provide no signiﬁcant
improvement in predicting PON1 levels over
a combination of PON1 polymorphisms
(Chen et al. 2005).
The gene frequencies for speciﬁc alleles of
PON1 genes vary by ethnicity, implying dif-
ferential susceptibility to pesticides among dif-
ferent ethnic groups (Allebrandt et al. 2002;
Brophy et al. 2002). In a study of mothers and
newborns from New York, a noticeable differ-
ence in haplotype frequency was observed
among three ethnic groups (Chen et al. 2005).
In the present study, we examined the
frequencies and haplotypes of ﬁve PON1 poly-
morphisms in coding regions (192QR and
55LM) and promoter regions (–162AG, –909CG,
and –108CT) and their associations with PON1
plasma levels and enzyme activities in pregnant
Latina women and their newborns living in the
Salinas Valley, California, an agricultural com-
munity (Eskenazi et al. 2003) where approxi-
mately 500,000 pounds of OP pesticides are
used annually (California Environmental
Protection Agency 2002). Additionally, we
report results of PON1 linkage analysis for ﬁve
PON1 polymorphisms and estimate the predic-
tive value of haplotypes, compared with PON1
genotypes, for PON1 plasma levels. The pre-
sent study follows our recent publications
demonstrating that the Salinas Valley popula-
tion has a relatively high level of exposure to
OP compounds (Bradman et al. 2005) and that
OP exposure as assessed by maternal dialkyl
phosphate metabolite levels was associated with
shorter gestational age (Eskenazi et al. 2004)
and increased frequency of abnormal reﬂexes in
neonates (Young et al. 2005).
Materials and Methods
Subjects and recruitment. Pregnant women
(n = 130) and their newborns (n = 130) were
randomly selected from the CHAMACOS
(Center for the Health Assessment of Mothers
and Children of Salinas) cohort, a longitudinal
birth cohort study of the effects of pesticides
and other environmental exposures on the
health of pregnant women and their children
living in the Salinas Valley, California. Women
were eligible for enrollment in the CHAMA-
COS study if they were ≥ 18 years of age, < 20
weeks’ gestation at enrollment, English- or
Spanish-speaking, Medi-Cal eligible, and plan-
ning to deliver at the Natividad Medical Center
(Bradman et al. 2005; Eskenazi et al. 2003,
2004; Young et al. 2005). All women in the
subcohort described here were representative of
the CHAMACOS cohort; they were Latina by
ethnicity, including 85% born in Mexico and
the remainder in the United States. Most of
the participants never smoked (> 92%), had
relatively high pesticide exposures based on
diethyl phosphate urinary metabolites (median,
20 nmol/L; range, 7–560 nmol/L), and
worked in agriculture during pregnancy
(39%). Fathers were more likely to smoke
(11%) and work in agriculture (72%) than
were mothers. Study protocols were approved
by the University of California, Berkeley, and
the University of Washington human-subject
review committees in compliance with all
applicable requirements. Written informed
consent was provided by all subjects.
Biologic samples collection and processing.
We collected blood from mothers at the time
of their glucose tolerance test (26.1 ±
2.3 weeks) and in the hospital shortly before
or after delivery. Blood samples were also col-
lected from the umbilical cords by delivery
room staff once the baby was safely delivered.
Heparinized whole blood was centrifuged,
divided into plasma, buffy coats, and red
blood cells, and then stored at –80°C. BD
Vacutainers (Becton Dickinson, Franklin
Lakes, NJ) without anticoagulant were used to
collect serum and clot. Processed plasma sam-
ples were stored at –80°C before being shipped
on dry ice to the University of Washington,
Seattle, for analysis of enzyme activity.
DNA was isolated from blood clots. Blood
clots thawed in a 37°C water bath were first
mechanically disrupted using ClotSpin tubes
(Gentra Systems Inc., Minneapolis, MN). The
Qiagen protocol (Qiagen Inc., Santa Clarita,
CA) was slightly modiﬁed by prolonging the
initial lysis and protease digestion step to
overnight incubation. DNA concentration was
measured using PicoGreen (Molecular Probes
Inc., Eugene, OR), adjusted to 10 ng/µL,
plated in 96-well plates, and stored at –80°C.
Samples were transferred to 384-well plates for
analysis of multiple SNPs, using robotic equip-
ment to avoid manual pipetting errors and for
time efﬁciency.
PON1 genotyping. Genotyping was con-
ducted by the University of California,
Berkeley, and Children’s Hospital Research
Institute Genotyping Core. Taqman real-time
polymerase chain reaction method was used
for genotyping of the –162AG, 55LM, and
192QR polymorphisms. Briefly, primers for
these SNPs were custom designed by Applied
Biosystems Inc. (Foster City, CA). Ampliﬂuor
allele-speciﬁc primers were used for genotyp-
ing of –909CG and –108CT. Genotype calling
was performed either manually using a spread-
sheet (Chemicon AssayAuditor, for real-time
data) or by automatic allele calling in SDS 2.1
(Applied Biosystems, for end-point data).
Quality assurance procedures included
assessment of randomly distributed blank
samples in each plate, duplicates of randomly
selected samples with independently isolated
DNA from the same subjects, and internal
controls. Repeated analysis in several runs
showed a high degree (96.5%) of concor-
dance, and the most robust call was selected in
the case of discordance (3.5%). Furthermore,
the assays were repeated for all low-conﬁdence
samples until a reliable call was obtained,
using a combination of the TaqMan and
Amplifluor methods for a subset of samples.
Additional analysis was performed indepen-
dently at the University of Washington for
10% of the DNA samples for the 192QR poly-
morphism by standard polymerase chain reac-
tion method (details given by Richter et al.
2004) with approximately 95% concordance;
all discrepancies were resolved by repeated
runs. Quality control software was used to
check data for Mendelian errors, and if those
were noted, the whole run was repeated.
Enzyme assays. Plasma was frozen at
–80°C until analysis. We measured three
PON1 enzyme activities in plasma from moth-
ers and children, using paraoxonase (POase),
chlorpyrifos oxonase (CPOase), and phenylac-
etate arylesterase (AREase) according to pub-
lished protocols (Jarvik et al. 2003; Richter and
Furlong 1999; Richter et al. 2004). We used
PON1 plasma levels (AREase assay) to analyze
the genetic effect because, unlike POase and
CPOase levels, they are not affected by differ-
ential catalytic efﬁciency primarily controlled
by the PON1192 SNP and have been shown to
correspond with PON1 levels determined by
immunologic methods (Blatter-Garin et al.
1994; Furlong et al. 1993). Together, these
three assays provide comprehensive informa-
tion about PON1 enzyme activities regarding
different substrates. Assessment of PON1
activities in mothers was ﬁrst conducted for 25
pregnant women at two different time points,
at 26 weeks and at delivery. PON1 activities
were not statistically different between the two
time points for all three PON1 enzyme assays
(r = 0.77–1.0, p < 0.0001). Therefore, we per-
formed analyses of AREase, POase, and
CPOase in the remainder of 105 Latina moth-
ers at one time point only—at 26 weeks’ gesta-
tion. Children in the study were of both sexes,
and girls represented 54%. No sex differences
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Table 1. PON1 allelic frequencies in Latino mothers
and their newborns.
Position Mother Children Total
in PON1 SNP (n = 130) (n = 130) (n = 260)
–909 C 0.48 0.44 0.46
G 0.52 0.56 0.54
–162 A 0.21 0.19 0.20
G 0.79 0.81 0.80
–108 C 0.51 0.55 0.53
T 0.49 0.45 0.47
55 L 0.82 0.82 0.82
M 0.18 0.18 0.18
192 Q 0.46 0.51 0.48
R 0.54 0.49 0.52in PON1 enzyme levels or genotypes were
observed, as is consistent with the available
PON1 literature (Costa et al. 2002).
Statistical analysis. Standard analyses for
all genotype data included analysis for Hardy-
Weinberg equilibrium, pairwise linkage dise-
quilibrium (LD), and haplotype assignment
using algorithms implemented in the publicly
available Haploview software (Battett et al.
2005), including PYPOP (Lancaster et al.
2003), tagSNPs (Stram et al. 2003), and
PHASE (Stephens et al. 2001, 2003). The LD
statistic D´ was calculated for each pair of ﬁve
PON1 SNPs, and R2 values were used to
describe the haplotype structure of the PON1
gene in our Latino cohort. PYPOP, tagSNPs,
and PHASE software methods showed similar
results. We used PHASE to generate the data
reported in this article, because it has been
shown to reduce error rates in haplotype
reconstruction compared with the expectation
maximization algorithm (Stephens and
Donelly 2003).
Subjects were grouped according to their
imputed diplotypes (Chen et al. 2005). When
more than one diplotype was possible for an
individual, only the most likely imputed haplo-
types were used in this analysis. The distribu-
tions and descriptive statistics were established
separately for each of the three PON1 enzyme
assays in mothers and in their newborns for
each of the five SNPs. The distributions of
enzyme activities were approximately normal.
Linear regression and backward regression
models were used to determine whether the
additional information for all five polymor-
phisms altered the effect of genotype on
enzyme activity. Coefﬁcients of determination
(total R2) were calculated for the proportion of
variability in PON1 plasma levels explained by
the ﬁve SNP genotypes (used as ordinal vari-
ables) and by imputed haplotypes. Each haplo-
type with > 5% frequency was coded as a
variable in the linear regression model, where
the values 0, 1, or 2 denoted the presence of
zero, one, or two copies of the haplotype for a
subject. Haplotypes with < 5% frequency were
pooled into one group for this analysis. All
analyses were conducted in STATA software
(version 8.0; StataCorp., College Station, TX)
and SAS software (version 9.1; SAS Institute
Inc., Cary, NC).
Results
PON1 polymorphisms. PON1 gene frequen-
cies were established for two coding polymor-
phisms (PON1192 and PON155) and three
promoter region polymorphisms (PON1–909,
PON1–162, PON1–108) (Table 1). As expected,
the ﬁve polymorphisms had similar allelic fre-
quencies in 130 pregnant Latina women of
Mexican descent and their newborns. All
genotypes were consistent with Hardy-
Weinberg equilibrium (data not shown). The
SNPs at position PON1–162 of the promoter
region and PON155 in the coding region had
lower variant allele frequencies (–162A, 55M)
than did the major allele, whereas the other
three polymorphisms (PON1–909, PON1–108,
and PON1192) had approximately equal pres-
ence of both alleles in this population.
Speciﬁcally, the frequencies of PON1192 alleles
were Q = 0.46, R = 0.54 in mothers, and Q =
0.51, R = 0.49 in children, with overall popu-
lation prevalence Q ~ R ~ 0.5. Frequencies for
the major alleles of promoter polymorphisms
PON1G–909, PON1G–162, and PON1C–108
were, respectively, 0.52, 0.78, and 0.51 in
mothers and 0.56, 0.81, and 0.55 in children,
and the frequency of a major allele of the cod-
ing PON1L55 polymorphism equaled 0.82 in
both age groups.
Results of linkage analysis between five
PON1 polymorphisms were also similar for
Latina mothers and their newborns (Table 2).
We observed nearly complete LD among the
three promoter polymorphisms (D´ = 0.8–1;
p < 0.001). Strong LD (D´ = 0.87 and 0.94 in
mothers and children, respectively; p < 0.001)
was found between the two coding polymor-
phisms (PON1192 and PON155). There was a
more complex relationship between coding
and promoter region polymorphisms:
although PON155 had high LD with all three
promoter polymorphisms (D´ = 0.74–1), only
two (PON1–108 and PON1–909) of the three
promoter SNPs were linked to PON1192 (D´
= 0.22 and 0.19 in mothers, and D´ = 0.27
and 0.34 in children, respectively). These
LDs were all modest but statistically signifi-
cant. However, no linkage was demonstrated
between SNPs at positions PON1192 and
PON1–162 (D´ = 0.0 in mothers and 0.18 and
children; p > 0.4).
Haplotype analysis. Haplotype analysis
revealed a total of 32 different combinations
of alleles (Table 3). However, their frequencies
were noticeably different and fall into three
distinct groups: a) a main group contributing
approximately 93% of all haplotypes for this
cohort, which is composed of seven haplo-
types with individual frequencies ranging from
7 to 24%; b) a second group with individual
frequencies ranging from 0.1 to 1.9%, which
contributes 5.5–7.8% of all haplotypes in
mothers and children; and c) a group of 17
rare haplotypes contributing a total of approx-
imately 1% of haplotype variability.
PON1 enzyme activities. AREase levels
allow for a comparison of PON1 levels across
genotypes because the catalytic efficiency of
hydrolysis of phenylacetate is not affected by
the PON1192 polymorphism (Tables 4, 5). The
AREase activity in mothers ranged from 19.8
to 281.4 U/mL and in newborns, from 4.3 to
110.7 U/mL. The mean AREase values for
mothers were similar across three PON1192
genotypes (Q/Q = 151.9 U/mL; Q/R = 144.3
U/L; R/R = 152.2 U/L; p = 0.64). In cord
samples, the Q192R polymorphism slightly
inﬂuenced AREase levels with PON1R192 indi-
viduals having the highest average levels (Q/Q
= 30.8 U/mL; Q/R = 35.8 U/mL; R/R = 42.9
U/ mL), although the difference between geno-
types was not statistically signiﬁcant (p = 0.13).
AREase levels varied noticeably across
C-108T genotypes in mothers (C/C =
163.6 U/mL; C/T = 147.1 U/mL; T/T =
134.8 U/mL; p = 0.04) with a larger gradient
in newborns (C/C = 48.7 U/mL; C/T = 34.0
PON1 in Latino mothers and newborns
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Table 2. Tests of PON1 LD in Latino mothers and children.
Position 192 55 –162 –909
in PON1 D´ χ2 p-Value D´ χ2 p-Value D´ χ2 p-Value D´ χ2 p-value
Mothers
–108 0.22 6.0 0.01 0.74 17.9 < 0.001 0.81 35.1 < 0.001 0.90 182.0 < 0.001
–909 0.19 4.7 0.03 0.75 19.5 < 0.001 1.00 57.9 < 0.001
–162 < 0.01 0.0 0.94 1.00 7.1 0.01
55 0.88 29.7 < 0.001
192
Children
–108 0.27 6.9 0.007 0.60 12.9 < 0.001 0.70 18.4 < 0.001 0.95 174.8 < 0.001
–909 0.34 9.9 0.002 0.72 19.1 < 0.001 1.00 38.7 < 0.001
–162 0.18 0.7 0.41 0.63 2.7 0.11
55 0.94 35.7 < 0.001
192
Table 3. Haplotypes (%) of ﬁve PON1 polymorphisms
in 130 Latino mothers and their newborns.
Haplotype Mothers Children
A:T:G:C:Ta 17.3 16.3
G:T:G:C:T 16.6 24.3
G:T:G:G:C 16.4 17.4
A:A:G:C:T 12.3 11.8
A:T:G:G:C 10.4 8.0
G:T:A:G:C 9.1 8.8
A:T:A:G:C 9.0 6.7
Group 1, total  91.1 93.3
A:A:G:G:C 1.9 1.9
G:T:G:C:C 1.8 0.9
G:T:A:G:T 1.0 0.5
G:A:G:G:C 1.0 0.1
A:T:A:G:T 0.9 0.9
A:A:A:G:C 0.7 1.2
A:T:G:G:T 0.5 —
Group 2, total 7.8 5.5
Other 1.1 1.2
aPolymorphisms in ﬁve loci of PON1 gene are listed in the
following order: 192(A/G), 55(A/T), –162(A/G), –909(C/G),
–108(C/T).U/mL; T/T = 27.3 U/mL; p = 0.0003).
AREase levels also differed by the L55M poly-
morphism in cord blood (p < 0.0001) but not
in maternal blood (p = 0.44), with M/M
homozygotes having the lowest levels in chil-
dren (17.6 U/mL) and in mothers (135.6
U/mL). AREase levels were signiﬁcantly higher
in subjects with the G-909 and A-162 alleles in
both mothers and children (p = 0.0003–0.03).
Mean POase and CPOase activities in
mothers were signiﬁcantly higher (1024.2 and
9358.3 U/L, respectively) than in newborns
(315.1 and 2663.4 U/L, respectively) (Tables
4, 5). Both POase and CPOase activity levels
demonstrated a strong association with the
PON1192 genotype. The lowest mean average
POase activity was seen in 192QQ children
(81.2 U/L) and the highest in 192RR mothers
(1927.9 U/L), resulting in a 24-fold difference
among these two genotype/age groups.
Furthermore, the lowest overall POase level
(10.3 U/L) was observed in the 192QQ new-
born child, and the highest in 192RR adult
(3014.2 U/L), bringing the overall difference
among individuals from the same population
to 300-fold. For CPOase, respective differ-
ences in enzyme activity between the lowest
and highest levels in this cohort reached
70-fold. Both POase and CPOase activities
also varied significantly by the other four
PON1 polymorphisms, with the lowest values
for –909GG, –162GG, –108TT, and 55MM
homozygote groups (p < 0.001 in children; p <
0.03 in mothers).
Overall, PON1 activity levels in maternal
blood were significantly higher than in cord
blood for all enzyme assays and all genotypes
(p < 0.001). Specifically, maternal POase,
CPOase, and AREase levels were 3.3-fold,
3.6-fold, and 4.0-fold higher, respectively,
than those in newborn. As expected, AREase,
CPOase, and POase levels correlated well
within PON1192 genotypes. In mothers, the
correlations between AREase and CPOase
levels ranged between 0.62 and 0.74 in QQ,
QR, and RR groups, and in newborns, these
correlations were even stronger, 0.90–0.92
(all p-values < 0.0001 for both mothers and
newborns). The correlations between AREase
and POase, and between POase and CPOase
were the highest in RR newborns (both 0.93)
and mothers (0.7 and 0.95, respectively), and
somewhat lower for other maternal and new-
born PON1192 genotype groups (all p-values
less than 0.001). AREase activity was not
compared with either CPOase or POase
across genotypes because of the differential
effects of the PON1192 polymorphism on
CPOase or POase activities. For example, the
PON1Q192 alloform hydrolyzes paraoxon with
a catalytic efficiency nine times lower than
PON1R192 (Li et al. 2000).
Phenotypic effects of PON1 genotype and
haplotype. We constructed linear regression
models to determine the proportion of the
variance of AREase explained by the five
PON1 polymorphisms and the imputed hap-
lotypes. The five PON1 genotype polymor-
phisms explained 8.1 and 23.1% of the
variance of AREase in mothers and newborns,
respectively. The coefﬁcient of variation (R2)
was similar for both promoter polymorphisms
PON1–909 and PON1–162 in mothers (~5%)
and children (~14%) after adjusting for
PON1–108. PON1 haplotypes did not signiﬁ-
cantly improve the amount of variance
explained (total R2 = 8.8% for mothers,
26.3% for newborns). The genetic contribu-
tion to AREase levels was signiﬁcantly higher
in newborns than in their mothers (p < 0.01).
Because POase and CPOase characterize
PON1 catalytic efficiency and are primarily
controlled by PON1192 polymorphism, a
comparison of haplotype and genotype effects
by these two assays was not relevant.
Discussion
To our knowledge, this is the first study to
report three PON1 enzyme activity levels in a
large cohort of newborns and mothers from
an agricultural cohort with relatively high lev-
els of OP exposure. Two main PON1 factors
are likely to contribute to the risk of adverse
health effects of OP exposure: the level of
enzyme (as measured by AREase assay) and
the ability of this enzyme to detoxify OP
metabolites (as measured in this study by
CPOase assay, and primarily affected by
PON1192). Thus, newborn children in this
cohort, based on their lower PON1 plasma
levels and detoxifying activities, are likely to
be signiﬁcantly more susceptible to OP expo-
sure than are their mothers. Similar to results
of a study from Mexico (Rojas-Garcia et al.
2005), we found large interindividual vari-
ability in PON1 plasma levels in both moth-
ers and children, with a 14-fold difference in
AREase among mothers, a 25-fold difference
in newborns, and an overall range of 65-fold
in this cohort. Additionally, we observed a
range of 70-fold for CPOase and 300-fold for
POase. However, it is important to emphasize
that POase variability does not reﬂect differ-
ential sensitivity to paraoxon exposure based
on recent animal data (Li et al. 2000). On the
other hand, PON1 levels and PON1192 poly-
morphism are very important in determining
sensitivity to chlorpyrifos and chlorpyrifos
oxon exposure (Cole et al. 2005; Furlong
et al. 2006). Further, AREase variability pri-
marily defines sensitivity to diazoxon expo-
sure (Furlong et al. 2006; Li et al. 2000).
Moreover, given the wide range in enzyme
Holland et al.
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Table 4. PON1 polymorphism frequencies and enzyme activities in Latina mothers (n = 130).
AREase (U/mL) POase (U/L) CPOase (U/L)
Genotype Percent Mean (range) p-Value Mean (range) p-Value Mean (range) p-Value
–909 100.0
CC 25.4 131.7 (54.5–233.7) 773.9 (150.5–2538.8) 8104.5 (3975.8–15389.2)
GC 46.1 149.6 (19.8–242.8) 0.03 981.8 (66.1–2866.0) 0.001 9522.0 (1661.7–17098.0) 0.001
GG 28.5 160.7 (78.9–281.4) 1324.1 (217.4–3014.2) 10492.6 (4535.9–16732.4)
–162 100.0
AA 5.4 172.8 (78.9–281.4) 1570.1 (397.3–2373.1) 10766.3 (6465.7–15723.8)
AG 31.5 160.8 (82.9–261.9) 0.02 1102.4 (217.4–3014.2) 0.03 10162.8 (4535.9–17098.0) 0.03
GG 63.1 139.8 (19.8–239.3) 939.4 (66.1–2866.0) 8958.8 (1661.7–16203.2)
–108 100.0
CC 27.3 163.6 (78.9–281.4) 1388.7 (217.4–3014.2) 10762.1 (4535.9–16732.4)
CT 46.9 147.1 (19.8–242.8) 0.04 982.8 (66.1–2866.0) 0.0003 9342.1 (1661.7–17098.0) 0.001
TT 25.8 134.8 (54.5–233.7) 768.3 (150.5–2538.8) 8283.2 (3975.8–15389.2)
55 100.0
LL 66.9 151.7 (54.5–281.4) 1181.4 (150.5–3014.2) 9982.5 (3975.8–17098.0)
LM 29.2 141.6 (19.8–242.8) 0.44 770.1 (66.1–1638.6) 0.0001 8541.7 (1661.7–13798.5) 0.002
MM 3.9 135.6 (102.0–185.5) 250.3 (212.0–339.7) 6684.0 (5391.1–9653.5)
192 100.0
QQ 30.0 151.9 (19.8–237.5) 340.7 (66.1–571.1) 8848.4 (1661.7–15389.2)
QR 46.9 144.3 (72.9–261.9) 0.64 1064.0 (565.4–2058.8) < 0.0001 9346.5 (4992.0–17098.0) 0.03
RR 23.1 152.2 (78.9–281.4) 1927.9 (1114.9–3014.2) 10577.1 (6465.7–16203.2)
All genotypes 149.2 (19.8–281.4) 1024.2 (66.1–3014.2) 9358.3 (1661.7–17098.0)levels, some of the mothers are predicted to
have an elevated susceptibility because they
have levels as low as most of the newborns.
In nine children followed longitudinally,
PON1 reached plateaus comparable with
mean adult levels between 6 and 24 months
of age (Cole et al. 2003). Our finding that
CHAMACOS mothers had approximately
4-fold higher AREase levels than did their
newborns confirms previous observations of
lower PON1 activities in small groups of
neonates compared with adults (Augustinsson
and Barr 1963; Ecobichon and Stephens
1973; Mueller et al. 1983). Our finding is
also consistent with a recent report where
neonates had 2.6- to 4.6-fold lower PON1
levels compared with mothers in three ethnic
groups residing in New York (Chen et al.
2003). However, no previous study has
reported either POase or CPOase variability
in such a large cohort of newborns.
In Latino newborns of the CHAMACOS
cohort, all three PON1 promoter polymor-
phisms as well as PON155 were significantly
associated with AREase levels in children, and
a greater proportion of the variance in AREase
enzyme levels was explained by genetic poly-
morphisms in newborns than in mothers. The
association of these polymorphisms and
AREase levels is in agreement with another
study of PON1 levels in newborns (Chen
et al. 2005). There was a nearly complete LD
among the three promoter region polymor-
phisms, as also observed in other studies
(Brophy et al. 2001a; Chen et al. 2005; James
et al. 2000; Rojas-Garcia et al. 2005).
However, PON1192 was not in LD with pro-
moter SNP PON1–162 and was in weak LD
with the PON1–108 and PON1–909. The lack
of strong LD between PON1192 and promoter
polymorphisms is also in agreement with data
from the Hispanic population in New York
City (Chen et al. 2005). We found stronger
LD between the two coding-region SNPs,
PON1192 and PON155, in both mothers and
children (D´ = 0.88 and 0.94, respectively) of
the CHAMACOS cohort compared with
Hispanics in New York City (Chen et al.
2005). The differences in linkage pattern may
be attributed to variation among ethnic
groups (Koda et al. 2004).
It has been reported that the association of
the M55 allele with low PON1 levels is pri-
marily attributable to LD with the inefﬁcient
T-108 allele (Brophy et al. 2001b). PON1M55
has also been reported to be somewhat less sta-
ble than PON1L55, additionally affecting pro-
tein levels in plasma (James et al. 2000). This
may explain why in CHAMACOS mothers,
who have about a 4-fold higher AREase levels
than the newborns, the effect of PON155 was
not statistically signiﬁcant.
Our analysis of five PON1 SNPs in a
Latino population of Mexican descent living in
California suggests that these SNPs may be
located on separate haplotype blocks because
we found nearly complete LD among the cod-
ing SNPs but not between PON1192 and
PON1–162 The presence of several haplotypes
blocks in the PON1 gene has been previously
reported for other ethnic groups (International
HapMap Consortium 2003; Koda et al.
2004). This underscores the importance of fur-
ther analysis of PON1 genetic variability. The
gene frequencies for speciﬁc alleles of PON1
genes vary by ethnicity, implying different
population susceptibility to pesticides (Costa
et al. 2002). The frequency of PON1192 alleles
in our Latina cohort of Mexican descent (Q =
0.5) was similar to those observed in Caribbean
Hispanic mothers and neonates in New York
City (both Q = 0.5) (Chen et al. 2003).
PON1–162 frequencies were also comparable in
these two populations (~ 0.8). However, the
frequencies for the PON1–108, PON1–909, and
PON155 were noticeably different between
Latinos from California and New York. The
PON1192 frequency in Hispanics from
Washington State (Q = 0.6) was slightly higher
than in New York and California (Brophy
et al. 2002). In previous studies, the allele fre-
quencies for PON1192 polymorphism in
Caucasians was Q = 0.7, whereas for African
Americans and other groups of African
descent, the PON1192 frequencies are reversed,
Q = 0.3 (Brophy et al. 2002).
Allebrandt et al. (2002) have compared a
combination of the PON1192 and PON155
allele frequencies across various ethnic groups.
Using this approach, Mexican Latinos of the
CHAMACOS cohort appear to be equally
differentiated from Caucasians, Asians, and
African Americans, which is consistent with
their Native American background, whereas
Caribbean Hispanics from New York (Chen
et al. 2003) are closer to Africans and
Caucasians (data not shown). This difference
across ethnic groups corroborates genetic and
historical information about these populations
(Cavalli-Sforza et al. 1993).
An effect of both PON1 genotype and
haplotypes on PON1 phenotype as measured
by AREase was stronger in CHAMACOS
newborns. This is in agreement with another
study (Chen et al. 2005; Wetmur et al. 2005)
that evaluated the relationship of ﬁve PON1
SNPs with enzyme activity in mothers and
their newborns. It is also clear that polymor-
phisms characterized to date in the PON1 gene
account for only a portion of the variability in
PON1 levels observed among individuals.
Additional research needs to be carried out to
identify other factors (e.g., trans-acting factors,
PON1 in Latino mothers and newborns
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Table 5. PON1 polymorphism frequencies and enzyme activities in Latino newborns (n = 130).
AREase (U/mL) POase (U/L) CPOase (U/L)
Genotype Percent Mean (range)  p-Value Mean (range)  p-Value Mean (range)  p-Value
–909 100.0
CC 14.0 24.2 (6.3–110.7) 222.8 (10.3–802.6) 1993.9 (245.7–7664.0)
GC 60.4 34.1 (4.3–108.8) 0.0001 272.6 (34.2–1235.8) 0.0004 2452.3 (485.2–7004.4) 0.0002
GG 25.6 48.9 (8.2–104.2) 431.4 (66.1–1352.0) 3395.5 (1231.3–7669.4)
–162 100.0
AA 3.1 57.7 (43.2–90.8) 707.4 (314.6–1352.0) 4977.3 (2715.3–7669.4)
AG 31.8 42.6 (8.2–104.2) 0.006 317.4 (49.0–812.4) 0.0004 2819.8 (714.7–4851.5) 0.0002
GG 65.1 32.3 (6.3–110.7) 281.2 (10.3–1235.8) 2412.8 (245.7–7664.0)
–108 100.0
CC 27.6 48.7 (8.2–104.2) 426.3 (66.1–1352.0) 3359.5 (1231.3–7669.4)
CT 54.3 34.0 (5.9–108.8) 0.0003 283.8 (49.0–1235.8) 0.0003 2479.4 (988.4–7004.4) 0.0003
TT 18.1 27.3 (6.3–110.7) 214.9 (10.3–802.6) 2102.8 (245.7–7664.0)
55 100.0
LL 67.2 42.9 (5.9–110.7) 364.9 (60.4–1352.0) 3008.4 (714.7–7669.4)
LM 28.9 23.5 (4.3–50.4) < 0.0001 195.0 (34.2–454.9) < 0.0001 1902.0 (485.2–4108.1) < 0.0001
MM 3.9 17.6 (6.3–54.2) 92.0 (10.3–286.1) 1171.0 (245.7–2123.2)
192 100.0
QQ 20.0 30.8 (6.3–108.8) 81.2 (10.3–178.6) 2074.3 (245.7–4778.5)
QR 55.1 35.8 (4.3–110.7) 0.13 292.3 (34.2–802.6) < 0.0001 2587.8 (485.2–7664.0) 0.006
RR 23.9 42.9 (5.9–104.2) 543.3 (165.3–1352.0) 3214.6 (988.4–7669.4)
All genotypes 36.2 (4.3–110.7) 315.1 (10.3–1352.0) 2663.4 (245.7–7669.4)other PON1 polymorphisms including intronic
and exonic splice enhancing sequences) that
inﬂuence PON1 expression.
Individuals with low PON1 activity are
hypothesized to be at higher risk for any
adverse health effects of OP exposure. In the
only study to date to directly examine this
hypothesis, Berkowitz et al. (2004) reported
that in residents of east Harlem (the same
cohort described by Chen et al. 2003), low
PON1 plasma levels were associated with
smaller neonatal head circumference. Further,
although prenatal levels of the urinary
metabolite of chlorpyrifos—3,5,6-trichloro-2-
pyridinol (TCP)—were not associated with
any measure of fetal growth or length of gesta-
tion by itself, higher levels of TCP were associ-
ated with smaller head circumference in
children whose mothers had low expression
of PON1.
We previously reported in the CHAMA-
COS cohort that OP exposure as measured
by urinary dialkyl phosphate metabolite levels
of the mother during pregnancy was associ-
ated with shorter gestational duration
(Eskenazi et al. 2004) and poorer neonatal
reﬂexes (Young et al. 2005). A recent publica-
tion links PON1RR and PON2CC genotypes in
infants with increased risk of preterm delivery
in China (Chen et al. 2004). In future analy-
ses, we aim to expand the analyses of PON1
to the entire CHAMACOS cohort and to
determine whether PON1 levels modify the
previously observed relationship between
OP exposure and gestational duration and
neonatal development.
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